Arcus Biosciences (RCUS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Strategic Focus and Portfolio Overview

• Emphasis on R&D strength in small molecules with strong validation and unmet needs, led by casdatifan as the primary program.

• Casdatifan is seen as a $5–10 billion commercial opportunity, with 80% of resources allocated to its development next year.

• Robust immunology and inflammation (I&I) pipeline includes A2 antagonist, TNFR1 antagonist, STAT6, CCR6 inhibitors, and AB102, with 1–2 new molecules expected to enter the clinic annually.

• Strong cash position, funded into the second half of 2028, supporting ongoing and planned trials.

• Partnerships with Taiho Pharma, AstraZeneca, and BMS, with global rights to key assets except in certain Asian territories.

Casdatifan Clinical and Market Insights

• Casdatifan, a HIF-2a inhibitor, demonstrated best-in-class data in late-line ccRCC, with a 45% confirmed ORR and median PFS of 15.1 months at 100mg QD.

• Pooled analysis across all monotherapy cohorts (n=121) showed a 35% ORR and 12.2 months median PFS, exceeding benchmarks from other HIF-2a inhibitors and TKIs.

• Casdatifan was well tolerated, with a safety profile comparable to belzutifan; anemia and hypoxia rates were similar.

• Oncologists preferred casdatifan combined with dual immunotherapy (anti-PD1/anti-CTLA4) over anti-PD1/TKI regimens for first-line treatment.

• Casdatifan demonstrates superior efficacy and biomarker differentiation versus belzutifan, with deeper and longer suppression of erythropoietin production.

Clinical Development and Data Readouts

• Casdatifan’s first registrational study in second-line RCC to be fully enrolled by end of 2024, with data likely in early 2028.

• PEAK-1 Phase 3 trial (casdatifan + cabozantinib) is enrolling post-IO ccRCC patients, aiming for full enrollment by year-end 2026.

• Multiple first-line TKI-free and combination strategies are being explored, with plans to initiate a new Phase 3 study in 1L RCC by year-end 2026.

• Key 2024 data sets: 120-patient monotherapy update (including OS), 30+ patient frontline anti-PD-1 + casdatifan, and 40+ patient second-line casdatifan + cabo.

• January data showed only 7% primary progression with casdatifan + anti-PD-1, compared to 18–30% for other regimens.